0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Liposomal Doxorubicin Market Insights and Forecast to 2027
Published Date: June 2021
|
Report Code: QYRE-Auto-38O5182
Home | Market Reports | Business & Industrial | Pharmaceuticals & Biotech
Global Liposomal Doxorubicin Market Insights and Forecast to 2027

Global Liposomal Doxorubicin Market Insights and Forecast to 2027

Code: QYRE-Auto-38O5182
Report
June 2021
111 Pages
QYResearch
Region: Global,
Description
Table of Content
Tables & Figures
Liposomal Doxorubicin market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Liposomal Doxorubicin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type

5 ml
10 ml
25 ml
The classification of liposomal doxorubicin includes 5ml, 10 ml, etc. And the proportion of 10ml in 2020 is estimated about 88.77%.

Segment by Application

Breast Cancer
Liver Cancer
Kidney Cancer
Multiple Myeloma
Ovarian Cancer
Other
Liposomal doxorubicin is widely in breast cancer, liver cancer, kidney cancer, multiple myeloma, ovarian cancer, etc. the proportion of breast cancer in 2020 will be about 21.6%.

BY COMPANY

Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma

BY REGION

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
1 Study Coverage
1.1 Liposomal Doxorubicin Product Introduction
1.2 Market by Type
1.2.1 Global Liposomal Doxorubicin Market Size Growth Rate by Type
1.4.2 5 ml
1.4.3 10 ml
1.2.4 25 ml
1.3 Market by Application
1.3.1 Global Liposomal Doxorubicin Market Size Growth Rate by Application
1.3.2 Breast Cancer
1.3.3 Liver Cancer
1.3.4 Kidney Cancer
1.3.5 Multiple Myeloma
1.3.6 Ovarian Cancer
1.3.7 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Liposomal Doxorubicin Sales Estimates and Forecasts 2016-2027
2.2 Global Liposomal Doxorubicin Revenue Estimates and Forecasts 2016-2027
2.3 Global Liposomal Doxorubicin Revenue by Region: 2016 VS 2021 VS 2027
2.4 Global Top Liposomal Doxorubicin Regions by Sales
2.4.1 Global Top Liposomal Doxorubicin Regions by Sales (2016-2021)
2.4.2 Global Top Liposomal Doxorubicin Regions by Sales (2022-2027)
2.5 Global Top Liposomal Doxorubicin Regions by Revenue
2.5.1 Global Top Liposomal Doxorubicin Regions by Revenue (2016-2021)
2.5.2 Global Top Liposomal Doxorubicin Regions by Revenue (2022-2027)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Liposomal Doxorubicin Sales by Manufacturers
3.1.1 Global Top Liposomal Doxorubicin Manufacturers by Sales (2016-2021)
3.1.2 Global Top Liposomal Doxorubicin Manufacturers Market Share by Sales (2016-2021)
3.1.3 Global Top 10 and Top 5 Companies by Liposomal Doxorubicin Sales in 2020
3.2 Global Liposomal Doxorubicin Revenue by Manufacturers
3.2.1 Global Top Liposomal Doxorubicin Manufacturers by Revenue (2016-2021)
3.2.2 Global Top Liposomal Doxorubicin Manufacturers Market Share by Revenue (2016-2021)
3.2.3 Global Top 10 and Top 5 Companies by Liposomal Doxorubicin Revenue in 2020
3.3 Global Liposomal Doxorubicin Sales Price by Manufacturers
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Liposomal Doxorubicin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Liposomal Doxorubicin Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Liposomal Doxorubicin Sales by Type
4.1.1 Global Liposomal Doxorubicin Historical Sales by Type (2016-2021)
4.1.2 Global Liposomal Doxorubicin Forecasted Sales by Type (2022-2027)
4.1.3 Global Liposomal Doxorubicin Sales Market Share by Type (2016-2027)
4.2 Global Liposomal Doxorubicin Revenue by Type
4.2.1 Global Liposomal Doxorubicin Historical Revenue by Type (2016-2021)
4.2.2 Global Liposomal Doxorubicin Forecasted Revenue by Type (2022-2027)
4.2.3 Global Liposomal Doxorubicin Revenue Market Share by Type (2016-2027)
4.3 Global Liposomal Doxorubicin Price by Type
4.3.1 Global Liposomal Doxorubicin Price by Type (2016-2021)
4.3.2 Global Liposomal Doxorubicin Price Forecast by Type (2022-2027)
5 Market Size by Application
5.1 Global Liposomal Doxorubicin Sales by Application
5.1.1 Global Liposomal Doxorubicin Historical Sales by Application (2016-2021)
5.1.2 Global Liposomal Doxorubicin Forecasted Sales by Application (2022-2027)
5.1.3 Global Liposomal Doxorubicin Sales Market Share by Application (2016-2027)
5.2 Global Liposomal Doxorubicin Revenue by Application
5.2.1 Global Liposomal Doxorubicin Historical Revenue by Application (2016-2021)
5.2.2 Global Liposomal Doxorubicin Forecasted Revenue by Application (2022-2027)
5.2.3 Global Liposomal Doxorubicin Revenue Market Share by Application (2016-2027)
5.3 Global Liposomal Doxorubicin Price by Application
5.3.1 Global Liposomal Doxorubicin Price by Application (2016-2021)
5.3.2 Global Liposomal Doxorubicin Price Forecast by Application (2022-2027)
6 North America
6.1 North America Liposomal Doxorubicin Market Size by Type
6.1.1 North America Liposomal Doxorubicin Sales by Type (2016-2027)
6.1.2 North America Liposomal Doxorubicin Revenue by Type (2016-2027)
6.2 North America Liposomal Doxorubicin Market Size by Application
6.2.1 North America Liposomal Doxorubicin Sales by Application (2016-2027)
6.2.2 North America Liposomal Doxorubicin Revenue by Application (2016-2027)
6.3 North America Liposomal Doxorubicin Market Size by Country
6.3.1 North America Liposomal Doxorubicin Sales by Country (2016-2027)
6.3.2 North America Liposomal Doxorubicin Revenue by Country (2016-2027)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Liposomal Doxorubicin Market Size by Type
7.1.1 Europe Liposomal Doxorubicin Sales by Type (2017-2027)
7.1.2 Europe Liposomal Doxorubicin Revenue by Type (2017-2027)
7.2 Europe Liposomal Doxorubicin Market Size by Application
7.2.1 Europe Liposomal Doxorubicin Sales by Application (2017-2027)
7.2.2 Europe Liposomal Doxorubicin Revenue by Application (2017-2027)
7.3 Europe Liposomal Doxorubicin Market Size by Country
7.3.1 Europe Liposomal Doxorubicin Sales by Country (2017-2027)
7.3.2 Europe Liposomal Doxorubicin Revenue by Country (2017-2027)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Liposomal Doxorubicin Market Size by Type
8.1.1 Asia Pacific Liposomal Doxorubicin Sales by Type (2018-2027)
8.1.2 Asia Pacific Liposomal Doxorubicin Revenue by Type (2018-2027)
8.2 Asia Pacific Liposomal Doxorubicin Market Size by Application
8.2.1 Asia Pacific Liposomal Doxorubicin Sales by Application (2018-2027)
8.2.2 Asia Pacific Liposomal Doxorubicin Revenue by Application (2018-2027)
8.3 Asia Pacific Liposomal Doxorubicin Market Size by Region
8.3.1 Asia Pacific Liposomal Doxorubicin Sales by Region (2018-2027)
8.3.2 Asia Pacific Liposomal Doxorubicin Revenue by Region (2018-2027)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Liposomal Doxorubicin Market Size by Type
9.1.1 Latin America Liposomal Doxorubicin Sales by Type (2019-2027)
9.1.2 Latin America Liposomal Doxorubicin Revenue by Type (2019-2027)
9.2 Latin America Liposomal Doxorubicin Market Size by Application
9.2.1 Latin America Liposomal Doxorubicin Sales by Application (2019-2027)
9.2.2 Latin America Liposomal Doxorubicin Revenue by Application (2019-2027)
9.3 Latin America Liposomal Doxorubicin Market Size by Country
9.3.1 Latin America Liposomal Doxorubicin Sales by Country (2019-2027)
9.3.2 Latin America Liposomal Doxorubicin Revenue by Country (2019-2027)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
6 Middle East and Africa
6.1 Middle East and Africa Liposomal Doxorubicin Market Size by Type
6.1.1 Middle East and Africa Liposomal Doxorubicin Sales by Type (2016-2027)
6.1.2 Middle East and Africa Liposomal Doxorubicin Revenue by Type (2016-2027)
6.2 Middle East and Africa Liposomal Doxorubicin Market Size by Application
6.2.1 Middle East and Africa Liposomal Doxorubicin Sales by Application (2016-2027)
6.2.2 Middle East and Africa Liposomal Doxorubicin Revenue by Application (2016-2027)
6.3 Middle East and Africa Liposomal Doxorubicin Market Size by Country
6.3.1 Middle East and Africa Liposomal Doxorubicin Sales by Country (2016-2027)
6.3.2 Middle East and Africa Liposomal Doxorubicin Revenue by Country (2016-2027)
6.3.3 Turkey
6.3.4 Saudi Arabia
6.3.5 U.A.E
11 Company Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Corporation Information
11.1.2 Johnson & Johnson Overview
11.1.3 Johnson & Johnson Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Johnson & Johnson Liposomal Doxorubicin Product Description
11.1.5 Johnson & Johnson Related Developments
11.2 Sun Pharmaceutical
11.2.1 Sun Pharmaceutical Corporation Information
11.2.2 Sun Pharmaceutical Overview
11.2.3 Sun Pharmaceutical Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
11.2.4 Sun Pharmaceutical Liposomal Doxorubicin Product Description
11.2.5 Sun Pharmaceutical Related Developments
11.3 CSPC
11.3.1 CSPC Corporation Information
11.3.2 CSPC Overview
11.3.3 CSPC Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
11.3.4 CSPC Liposomal Doxorubicin Product Description
11.3.5 CSPC Related Developments
11.4 Kinyond
11.4.1 Kinyond Corporation Information
11.4.2 Kinyond Overview
11.4.3 Kinyond Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
11.4.4 Kinyond Liposomal Doxorubicin Product Description
11.4.5 Kinyond Related Developments
11.5 Teva
11.5.1 Teva Corporation Information
11.5.2 Teva Overview
11.5.3 Teva Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
11.5.4 Teva Liposomal Doxorubicin Product Description
11.5.5 Teva Related Developments
11.6 Fudan-Zhangjiang
11.6.1 Fudan-Zhangjiang Corporation Information
11.6.2 Fudan-Zhangjiang Overview
11.6.3 Fudan-Zhangjiang Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
11.6.4 Fudan-Zhangjiang Liposomal Doxorubicin Product Description
11.6.5 Fudan-Zhangjiang Related Developments
11.7 Zydus Cadila
11.7.1 Zydus Cadila Corporation Information
11.7.2 Zydus Cadila Overview
11.7.3 Zydus Cadila Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
11.7.4 Zydus Cadila Liposomal Doxorubicin Product Description
11.7.5 Zydus Cadila Related Developments
11.8 TTY Biopharma
11.8.1 TTY Biopharma Corporation Information
11.8.2 TTY Biopharma Overview
11.8.3 TTY Biopharma Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
11.8.4 TTY Biopharma Liposomal Doxorubicin Product Description
11.8.5 TTY Biopharma Related Developments
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Corporation Information
11.1.2 Johnson & Johnson Overview
11.1.3 Johnson & Johnson Liposomal Doxorubicin Sales, Price, Revenue and Gross Margin (2016-2021)
11.1.4 Johnson & Johnson Liposomal Doxorubicin Product Description
11.1.5 Johnson & Johnson Related Developments
12 Value Chain and Sales Channels Analysis
12.1 Liposomal Doxorubicin Value Chain Analysis
12.2 Liposomal Doxorubicin Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Liposomal Doxorubicin Production Mode & Process
12.4 Liposomal Doxorubicin Sales and Marketing
12.4.1 Liposomal Doxorubicin Sales Channels
12.4.2 Liposomal Doxorubicin Distributors
12.5 Liposomal Doxorubicin Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Liposomal Doxorubicin Industry Trends
13.2 Liposomal Doxorubicin Market Drivers
13.3 Liposomal Doxorubicin Market Challenges
13.4 Liposomal Doxorubicin Market Restraints
14 Key Findings in The Global Liposomal Doxorubicin Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
List of Tables
    Table 1. Global Liposomal Doxorubicin Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
    Table 2. Major Manufacturers of 5 ml
    Table 3. Major Manufacturers of 10 ml
    Table 4. Major Manufacturers of 25 ml
    Table 5. Global Liposomal Doxorubicin Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
    Table 6. Global Liposomal Doxorubicin Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
    Table 7. Global Liposomal Doxorubicin Sales by Region (2016-2021) & (K Unit)
    Table 8. Global Liposomal Doxorubicin Sales Market Share by Region (2016-2021)
    Table 9. Global Liposomal Doxorubicin Sales by Region (2016-2021) & (K Unit)
    Table 10. Global Liposomal Doxorubicin Sales Market Share by Region (2022-2027)
    Table 11. Global Liposomal Doxorubicin Revenue by Region (2016-2021) & (US$ Million)
    Table 12. Global Liposomal Doxorubicin Revenue Market Share by Region (2016-2021)
    Table 13. Global Liposomal Doxorubicin Revenue by Region (2022-2027) & (US$ Million)
    Table 14. Global Liposomal Doxorubicin Revenue Market Share by Region (2022-2027)
    Table 15. Global Liposomal Doxorubicin Sales by Manufacturers (2016-2021) & (K Unit)
    Table 16. Global Liposomal Doxorubicin Sales Share by Manufacturers (2016-2021)
    Table 17. Global Liposomal Doxorubicin Revenue by Manufacturers (2016-2021) & (US$ Million)
    Table 18. Global Liposomal Doxorubicin Revenue Share by Manufacturers (2016-2021)
    Table 19. Liposomal Doxorubicin Price by Manufacturers 2016-2021 (USD/Unit)
    Table 20. Global Liposomal Doxorubicin Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 21. Global Liposomal Doxorubicin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Liposomal Doxorubicin as of 2020)
    Table 22. Liposomal Doxorubicin Manufacturing Base Distribution and Headquarters
    Table 23. Manufacturers Liposomal Doxorubicin Product Offered
    Table 24. Date of Manufacturers Enter into Liposomal Doxorubicin Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Liposomal Doxorubicin Sales by Type (2016-2021) & (K Unit)
    Table 27. Global Liposomal Doxorubicin Sales by Type (2022-2027) & (K Unit)
    Table 28. Global Liposomal Doxorubicin Sales Share by Type (2016-2021)
    Table 29. Global Liposomal Doxorubicin Sales Share by Type (2022-2027)
    Table 30. Global Liposomal Doxorubicin Revenue by Type (2016-2021) & (US$ Million)
    Table 31. Global Liposomal Doxorubicin Revenue by Type (2022-2027) & (US$ Million)
    Table 32. Global Liposomal Doxorubicin Revenue Share by Type (2016-2021)
    Table 33. Global Liposomal Doxorubicin Revenue Share by Type (2022-2027)
    Table 34. Liposomal Doxorubicin Price by Type (2016-2021) & (USD/Unit)
    Table 35. Global Liposomal Doxorubicin Price Forecast by Type (2022-2027) & (USD/Unit)
    Table 36. Global Liposomal Doxorubicin Sales by Application (2016-2021) & (K Unit)
    Table 37. Global Liposomal Doxorubicin Sales by Application (2022-2027) & (K Unit)
    Table 38. Global Liposomal Doxorubicin Sales Share by Application (2016-2021)
    Table 39. Global Liposomal Doxorubicin Sales Share by Application (2022-2027)
    Table 40. Global Liposomal Doxorubicin Revenue by Application (2016-2021) & (US$ Million)
    Table 41. Global Liposomal Doxorubicin Revenue by Application (2022-2027) & (US$ Million)
    Table 42. Global Liposomal Doxorubicin Revenue Share by Application (2016-2021)
    Table 43. Global Liposomal Doxorubicin Revenue Share by Application (2022-2027)
    Table 44. Liposomal Doxorubicin Price by Application (2016-2021) & (USD/Unit)
    Table 45. Global Liposomal Doxorubicin Price Forecast by Application (2022-2027) & (USD/Unit)
    Table 46. North America Liposomal Doxorubicin Sales by Type (2016-2021) & (K Unit)
    Table 47. North America Liposomal Doxorubicin Sales by Type (2022-2027) & (K Unit)
    Table 48. North America Liposomal Doxorubicin Revenue by Type (2016-2021) & (US$ Million)
    Table 49. North America Liposomal Doxorubicin Revenue by Type (2022-2027) & (US$ Million)
    Table 50. North America Liposomal Doxorubicin Sales by Application (2016-2021) & (K Unit)
    Table 51. North America Liposomal Doxorubicin Sales by Application (2022-2027) & (K Unit)
    Table 52. North America Liposomal Doxorubicin Revenue by Application (2016-2021) & (US$ Million)
    Table 53. North America Liposomal Doxorubicin Revenue by Application (2022-2027) & (US$ Million)
    Table 54. North America Liposomal Doxorubicin Sales by Country (2016-2021) & (K Unit)
    Table 55. North America Liposomal Doxorubicin Sales by Country (2022-2027) & (K Unit)
    Table 56. North America Liposomal Doxorubicin Revenue by Country (2016-2021) & (US$ Million)
    Table 57. North America Liposomal Doxorubicin Revenue by Country (2022-2027) & (US$ Million)
    Table 58. Europe Liposomal Doxorubicin Sales by Type (2016-2021) & (K Unit)
    Table 59. Europe Liposomal Doxorubicin Sales by Type (2022-2027) & (K Unit)
    Table 60. Europe Liposomal Doxorubicin Revenue by Type (2016-2021) & (US$ Million)
    Table 61. Europe Liposomal Doxorubicin Revenue by Type (2022-2027) & (US$ Million)
    Table 62. Europe Liposomal Doxorubicin Sales by Application (2016-2021) & (K Unit)
    Table 63. Europe Liposomal Doxorubicin Sales by Application (2022-2027) & (K Unit)
    Table 64. Europe Liposomal Doxorubicin Revenue by Application (2016-2021) & (US$ Million)
    Table 65. Europe Liposomal Doxorubicin Revenue by Application (2022-2027) & (US$ Million)
    Table 66. Europe Liposomal Doxorubicin Sales by Country (2016-2021) & (K Unit)
    Table 67. Europe Liposomal Doxorubicin Sales by Country (2022-2027) & (K Unit)
    Table 68. Europe Liposomal Doxorubicin Revenue by Country (2016-2021) & (US$ Million)
    Table 69. Europe Liposomal Doxorubicin Revenue by Country (2022-2027) & (US$ Million)
    Table 70. Asia Pacific Liposomal Doxorubicin Sales by Type (2016-2021) & (K Unit)
    Table 71. Asia Pacific Liposomal Doxorubicin Sales by Type (2022-2027) & (K Unit)
    Table 72. Asia Pacific Liposomal Doxorubicin Revenue by Type (2016-2021) & (US$ Million)
    Table 73. Asia Pacific Liposomal Doxorubicin Revenue by Type (2022-2027) & (US$ Million)
    Table 74. Asia Pacific Liposomal Doxorubicin Sales by Application (2016-2021) & (K Unit)
    Table 75. Asia Pacific Liposomal Doxorubicin Sales by Application (2022-2027) & (K Unit)
    Table 76. Asia Pacific Liposomal Doxorubicin Revenue by Application (2016-2021) & (US$ Million)
    Table 77. Asia Pacific Liposomal Doxorubicin Revenue by Application (2022-2027) & (US$ Million)
    Table 78. Asia Pacific Liposomal Doxorubicin Sales by Region (2016-2021) & (K Unit)
    Table 79. Asia Pacific Liposomal Doxorubicin Sales by Region (2022-2027) & (K Unit)
    Table 80. Asia Pacific Liposomal Doxorubicin Revenue by Region (2016-2021) & (US$ Million)
    Table 81. Asia Pacific Liposomal Doxorubicin Revenue by Region (2022-2027) & (US$ Million)
    Table 82. Latin America Liposomal Doxorubicin Sales by Type (2016-2021) & (K Unit)
    Table 83. Latin America Liposomal Doxorubicin Sales by Type (2022-2027) & (K Unit)
    Table 84. Latin America Liposomal Doxorubicin Revenue by Type (2016-2021) & (US$ Million)
    Table 85. Latin America Liposomal Doxorubicin Revenue by Type (2022-2027) & (US$ Million)
    Table 86. Latin America Liposomal Doxorubicin Sales by Application (2016-2021) & (K Unit)
    Table 87. Latin America Liposomal Doxorubicin Sales by Application (2022-2027) & (K Unit)
    Table 88. Latin America Liposomal Doxorubicin Revenue by Application (2016-2021) & (US$ Million)
    Table 89. Latin America Liposomal Doxorubicin Revenue by Application (2022-2027) & (US$ Million)
    Table 90. Latin America Liposomal Doxorubicin Sales by Country (2016-2021) & (K Unit)
    Table 91. Latin America Liposomal Doxorubicin Sales by Country (2022-2027) & (K Unit)
    Table 92. Latin America Liposomal Doxorubicin Revenue by Country (2016-2021) & (US$ Million)
    Table 93. Latin America Liposomal Doxorubicin Revenue by Country (2022-2027) & (US$ Million)
    Table 94. Middle East and Africa Liposomal Doxorubicin Sales by Type (2016-2021) & (K Unit)
    Table 95. Middle East and Africa Liposomal Doxorubicin Sales by Type (2022-2027) & (K Unit)
    Table 96. Middle East and Africa Liposomal Doxorubicin Revenue by Type (2016-2021) & (US$ Million)
    Table 97. Middle East and Africa Liposomal Doxorubicin Revenue by Type (2022-2027) & (US$ Million)
    Table 98. Middle East and Africa Liposomal Doxorubicin Sales by Application (2016-2021) & (K Unit)
    Table 99. Middle East and Africa Liposomal Doxorubicin Sales by Application (2022-2027) & (K Unit)
    Table 100. Middle East and Africa Liposomal Doxorubicin Revenue by Application (2016-2021) & (US$ Million)
    Table 101. Middle East and Africa Liposomal Doxorubicin Revenue by Application (2022-2027) & (US$ Million)
    Table 102. Middle East and Africa Liposomal Doxorubicin Sales by Country (2016-2021) & (K Unit)
    Table 103. Middle East and Africa Liposomal Doxorubicin Sales by Country (2022-2027) & (K Unit)
    Table 104. Middle East and Africa Liposomal Doxorubicin Revenue by Country (2016-2021) & (US$ Million)
    Table 105. Middle East and Africa Liposomal Doxorubicin Revenue by Country (2022-2027) & (US$ Million)
    Table 106. Johnson & Johnson Corporation Information
    Table 107. Johnson & Johnson Description and Major Businesses
    Table 108. Johnson & Johnson Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 109. Johnson & Johnson Liposomal Doxorubicin Product
    Table 110. Johnson & Johnson Recent Developments
    Table 111. Sun Pharmaceutical Corporation Information
    Table 112. Sun Pharmaceutical Description and Major Businesses
    Table 113. Sun Pharmaceutical Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 114. Sun Pharmaceutical Liposomal Doxorubicin Product
    Table 115. Sun Pharmaceutical Recent Developments
    Table 116. CSPC Corporation Information
    Table 117. CSPC Description and Major Businesses
    Table 118. CSPC Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 119. CSPC Liposomal Doxorubicin Product
    Table 120. CSPC Recent Developments
    Table 121. Kinyond Corporation Information
    Table 122. Kinyond Description and Major Businesses
    Table 123. Kinyond Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 124. Kinyond Liposomal Doxorubicin Product
    Table 125. Kinyond Recent Developments
    Table 126. Teva Corporation Information
    Table 127. Teva Description and Major Businesses
    Table 128. Teva Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 129. Teva Liposomal Doxorubicin Product
    Table 130. Teva Recent Developments
    Table 131. Fudan-Zhangjiang Corporation Information
    Table 132. Fudan-Zhangjiang Description and Major Businesses
    Table 133. Fudan-Zhangjiang Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 134. Fudan-Zhangjiang Liposomal Doxorubicin Product
    Table 135. Fudan-Zhangjiang Recent Developments
    Table 136. Zydus Cadila Corporation Information
    Table 137. Zydus Cadila Description and Major Businesses
    Table 138. Zydus Cadila Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 139. Zydus Cadila Liposomal Doxorubicin Product
    Table 140. Zydus Cadila Recent Developments
    Table 141. TTY Biopharma Corporation Information
    Table 142. TTY Biopharma Description and Major Businesses
    Table 143. TTY Biopharma Liposomal Doxorubicin Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2016-2021)
    Table 144. TTY Biopharma Liposomal Doxorubicin Product
    Table 145. TTY Biopharma Recent Developments
    Table 146. Key Raw Materials Lists
    Table 147. Raw Materials Key Suppliers Lists
    Table 148. Liposomal Doxorubicin Distributors List
    Table 149. Liposomal Doxorubicin Customers List
    Table 150. Liposomal Doxorubicin Market Trends
    Table 151. Liposomal Doxorubicin Market Drivers
    Table 152. Liposomal Doxorubicin Market Challenges
    Table 153. Liposomal Doxorubicin Market Restraints
    Table 154. Research Programs/Design for This Report
    Table 155. Key Data Information from Secondary Sources
    Table 156. Key Data Information from Primary Sources
List of Figures
    Figure 1. Liposomal Doxorubicin Product Picture
    Figure 2. Global Liposomal Doxorubicin Market Share by Type in 2020 & 2027
    Figure 3. 5 ml Product Picture
    Figure 4. 10 ml Product Picture
    Figure 5. 25 ml Product Picture
    Figure 6. Global Liposomal Doxorubicin Sales Market Share by Application in 2020 & 2027
    Figure 7. Breast Cancer
    Figure 8. Liver Cancer
    Figure 9. Kidney Cancer
    Figure 10. Multiple Myeloma
    Figure 11. Ovarian Cancer
    Figure 12. Other
    Figure 13. Liposomal Doxorubicin Report Years Considered
    Figure 14. Global Liposomal Doxorubicin Sales 2016-2027 (K Unit)
    Figure 15. Global Liposomal Doxorubicin Revenue, (US$ Million), 2016 VS 2021 VS 2027
    Figure 16. Global Liposomal Doxorubicin Revenue 2016-2027 (US$ Million)
    Figure 17. Global Liposomal Doxorubicin Revenue Market Share by Region in Percentage: 2020 Versus 2027
    Figure 18. Global Liposomal Doxorubicin Sales Market Share by Region (2016-2021)
    Figure 19. Global Liposomal Doxorubicin Sales Market Share by Region (2022-2027)
    Figure 20. North America Liposomal Doxorubicin Sales YoY (2016-2027) & (K Unit)
    Figure 21. North America Liposomal Doxorubicin Revenue YoY (2016-2027) & (US$ Million)
    Figure 22. Europe Liposomal Doxorubicin Sales YoY (2016-2027) & (K Unit)
    Figure 23. Europe Liposomal Doxorubicin Revenue YoY (2016-2027) & (US$ Million)
    Figure 24. Asia-Pacific Liposomal Doxorubicin Sales YoY (2016-2027) & (K Unit)
    Figure 25. Asia-Pacific Liposomal Doxorubicin Revenue YoY (2016-2027) & (US$ Million)
    Figure 26. Latin America Liposomal Doxorubicin Sales YoY (2016-2027) & (K Unit)
    Figure 27. Latin America Liposomal Doxorubicin Revenue YoY (2016-2027) & (US$ Million)
    Figure 28. Middle East & Africa Liposomal Doxorubicin Sales YoY (2016-2027) & (K Unit)
    Figure 29. Middle East & Africa Liposomal Doxorubicin Revenue YoY (2016-2027) & (US$ Million)
    Figure 30. The Top 10 and Top 5 Players Market Share by Liposomal Doxorubicin Sales in 2020
    Figure 31. The Top 10 and Top 5 Players Market Share by Liposomal Doxorubicin Revenue in 2020
    Figure 32. Liposomal Doxorubicin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
    Figure 33. Global Liposomal Doxorubicin Sales Market Share by Type (2016-2027)
    Figure 34. Global Liposomal Doxorubicin Revenue Market Share by Type (2016-2027)
    Figure 35. Global Liposomal Doxorubicin Sales Market Share by Application (2016-2027)
    Figure 36. Global Liposomal Doxorubicin Revenue Market Share by Application (2016-2027)
    Figure 37. North America Liposomal Doxorubicin Sales Market Share by Type (2016-2027)
    Figure 38. North America Liposomal Doxorubicin Revenue Market Share by Type (2016-2027)
    Figure 39. North America Liposomal Doxorubicin Sales Market Share by Application (2016-2027)
    Figure 40. North America Liposomal Doxorubicin Revenue Market Share by Application (2016-2027)
    Figure 41. North America Liposomal Doxorubicin Sales Share by Country (2016-2027)
    Figure 42. North America Liposomal Doxorubicin Revenue Share by Country (2016-2027)
    Figure 43. U.S. Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 44. Canada Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 45. Europe Liposomal Doxorubicin Sales Market Share by Type (2016-2027)
    Figure 46. Europe Liposomal Doxorubicin Revenue Market Share by Type (2016-2027)
    Figure 47. Europe Liposomal Doxorubicin Sales Market Share by Application (2016-2027)
    Figure 48. Europe Liposomal Doxorubicin Revenue Market Share by Application (2016-2027)
    Figure 49. Europe Liposomal Doxorubicin Sales Share by Country (2016-2027)
    Figure 50. Europe Liposomal Doxorubicin Revenue Share by Country (2016-2027)
    Figure 51. Germany Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 52. France Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 53. U.K. Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 54. Italy Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 55. Russia Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 56. Asia Pacific Liposomal Doxorubicin Sales Market Share by Type (2016-2027)
    Figure 57. Asia Pacific Liposomal Doxorubicin Revenue Market Share by Type (2016-2027)
    Figure 58. Asia Pacific Liposomal Doxorubicin Sales Market Share by Application (2016-2027)
    Figure 59. Asia Pacific Liposomal Doxorubicin Revenue Market Share by Application (2016-2027)
    Figure 60. Asia Pacific Liposomal Doxorubicin Sales Share by Region (2016-2027)
    Figure 61. Asia Pacific Liposomal Doxorubicin Revenue Share by Region (2016-2027)
    Figure 62. China Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 63. Japan Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 64. South Korea Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 65. India Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 66. Australia Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 67. Taiwan Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 68. Indonesia Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 69. Thailand Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 70. Malaysia Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 71. Philippines Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 72. Latin America Liposomal Doxorubicin Sales Market Share by Type (2016-2027)
    Figure 73. Latin America Liposomal Doxorubicin Revenue Market Share by Type (2016-2027)
    Figure 74. Latin America Liposomal Doxorubicin Sales Market Share by Application (2016-2027)
    Figure 75. Latin America Liposomal Doxorubicin Revenue Market Share by Application (2016-2027)
    Figure 76. Latin America Liposomal Doxorubicin Sales Share by Country (2016-2027)
    Figure 77. Latin America Liposomal Doxorubicin Revenue Share by Country (2016-2027)
    Figure 78. Mexico Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 79. Brazil Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 80. Argentina Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 81. Middle East and Africa Liposomal Doxorubicin Sales Market Share by Type (2016-2027)
    Figure 82. Middle East and Africa Liposomal Doxorubicin Revenue Market Share by Type (2016-2027)
    Figure 83. Middle East and Africa Liposomal Doxorubicin Sales Market Share by Application (2016-2027)
    Figure 84. Middle East and Africa Liposomal Doxorubicin Revenue Market Share by Application (2016-2027)
    Figure 85. Middle East and Africa Liposomal Doxorubicin Sales Share by Country (2016-2027)
    Figure 86. Middle East and Africa Liposomal Doxorubicin Revenue Share by Country (2016-2027)
    Figure 87. Turkey Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 88. Saudi Arabia Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 89. U.A.E Liposomal Doxorubicin Revenue (2016-2027) & (US$ Million)
    Figure 90. Liposomal Doxorubicin Value Chain
    Figure 91. Liposomal Doxorubicin Production Process
    Figure 92. Channels of Distribution
    Figure 93. Distributors Profiles
    Figure 94. Bottom-up and Top-down Approaches for This Report
    Figure 95. Data Triangulation
    Figure 96. Key Executives Interviewed
SELECT A FORMAT
Added to Cart

Electronic (PDF)
$4900
This license allows only one user to access the PDF.

Electronic (PDF)
$7350
This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Electronic (PDF)
$9800
This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
Nano String

RELATED REPORTS

Global Cytotoxicity Assay Market Size Status and Forecast 2021 2027
Global Cytotoxicity Assay Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-39V907
Sun Jul 18 00:00:00 UTC 2021

Add to Cart

Global Aquaculture Vaccine Market Size Status and Forecast 2021 2027
Global Aquaculture Vaccine Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-3I3192
Sun Jul 18 00:00:00 UTC 2021

Add to Cart

Global Intranasal Corticosteroids Market Size Status and Forecast 2021 2027
Global Intranasal Corticosteroids Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-25X2634
Sun Jul 18 00:00:00 UTC 2021

Add to Cart

Global Tumor Tracking System Market Size Status and Forecast 2021 2027
Global Tumor Tracking System Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-21F2812
Sun Jul 18 00:00:00 UTC 2021

Add to Cart